- Bebtelovimab
- FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant
- Frequently Asked Questions on the Emergency Use Authorization for Evusheld (tixagevimab copackaged with cilgavimab) for Pre-exposure Prophylaxis (PrEP) of COVID-19
- Frequently Asked Questions on the Emergency Use Authorization for Paxlovid for Treatment of COVID-19
- Frequently Asked Questions on the Emergency Use Authorization of Bebtelovimab for the Treatment of COVID-19
Contacts
Business Hours
| Mon: | 9:00 AM – 6:00 PM |
|---|---|
| Tue: | 9:00 AM – 6:00 PM |
| Wed: | 9:00 AM – 6:00 PM |
| Thu: | 9:00 AM – 6:00 PM |
| Fri: | 9:00 AM – 6:00 PM |
| Sat: | Closed |
| Sun: | Closed |
And then Add to Home Screen.